As expected, Z86 treatment reduced the phosphorylation of GSK3β (Ser9) and increased the levels of phospho-β-catenin (Ser33/Ser37/Thr41) in the tumor tissues compared with the vehicle-treated group. This evidence concerns the gene GSK3B and neoplasm.